Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize recent data on the use of antibodies to epidermal growth factor receptor in treatment of non-small-cell lung cancer
- Discuss the current status of the use of biomarkers in patient selection for treatment with epidermal growth factor receptor–targeting agents in non-small-cell lung cancer
- Summarize results of reported investigation of insulin-like growth factor type I receptor antibodies in initial therapy for patients with non-small-cell lung cancer
- Discuss reported data on maintenance therapy in non-small-cell lung cancer and their clinical implications
- Review recent data evaluating the efficacy of topoisomerase inhibitors in the treatment of patients with small-cell lung cancer
Topics covered include:
- FLEX Trial: In First-line NSCLC Treatment, Cetuximab Plus Cisplatin/Vinorelbine Shows Improved Survival
- Race and Survival: FLEX Subgroup Analysis
- Cetuximab in Combination With Chemoradiation for Stage IIIA/B NSCLC
- Cetuximab in NSCLC: What Are the Implications for Future Clinical Practice?
- KRAS Testing Before Cetuximab Treatment: Does Colorectal Cancer Experience Apply in NSCLC?
- Maintenance Pemetrexed in Advanced NSCLC
- Is Longer Chemotherapy Better? Mixed Results From Meta-analysis
- Novel Agents in NSCLC: Phase III Disappointments and Phase II Promise
- In Extensive-Disease SCLC, a Dearth of Positive Data